Comparative Pharmacology
Head-to-head clinical analysis: FORTAMET versus PRANDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAMET versus PRANDIN.
FORTAMET vs PRANDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Repaglinide stimulates insulin secretion from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Initial: 500 mg orally twice daily or 1000 mg orally once daily; titrate in increments of 500 mg weekly; maximum daily dose: 2000 mg.
0.5–4 mg orally 0–30 minutes before meals, typically 2–4 times daily. Maximum single dose: 4 mg. Maximum total daily dose: 16 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 6.2 hours (range 4–9 hours) in patients with normal renal function; half-life is prolonged in renal impairment (up to 18 hours in moderate impairment and 24 hours in severe impairment).
Terminal elimination half-life: 1.0-1.5 hours. Clinically, due to rapid elimination, repaglinide requires dosing before each meal to control postprandial glucose.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; the remainder is excreted fecally (via bile).
Primarily hepatic metabolism via CYP2C8 and CYP3A4; metabolites excreted in bile (90%) and urine (10%). Less than 0.1% excreted unchanged in urine.
Category C
Category C
Antidiabetic
Antidiabetic